RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @BMTjournal: High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myelo…
RT @MDonatoBMT: 45 mo PFS in the r/r MM setting is quite good. No NRM. Mel dose reduced for Crcl <70. #mmsm #bmtsm @MM_Hub https://t.co/dJc…
RT @BMTjournal: High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myelo…
RT @BMTjournal: High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myelo…
RT @BMTjournal: High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myelo…
RT @BMTjournal: High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myelo…
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma @BMTjournal #mmsm https://t.co/UtTe9C6kZC
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma | Bone Marrow Transplantation https://t.co/Z98bG9hFbW
Gomez Arteaga et al. BMT 2019. Phase 2 study of benadmustine + MEL ASCT conditioning in myeloma. No comparator; 0% TRM; 51% CR/sCR at day +100. PFS similar to IFM-2009 early transplant arm. PFS in relapsed/ref arm similar to newly diagnosed pts. https://t.
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
High-dose benda and mel conditioning for auto#SCT in #myeloma. 1. High-ish dose of Bendamustine, only for ?young/fit patients? 2. Worth looking into for high risk/2nd autoSCT at relapse. https://t.co/qGlmqEgC4R #bmtsm @udaypkulkarni @SubbaiahRm @haem_team
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
Is it a new conditioning regimen coming in myeloma? Let's hope trials be positive😃 https://t.co/PbH2xJwEUs
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma https://t.co/w23751KYjI
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
RT @AGomez_MD: Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @…
Congratulations to our excellent fellow on this publication!
Happy to share the results of our phase II trial of Bendamustine +Melphalan conditioning regimen in myeloma, now published @BMTjournal . Link https://t.co/dlilrPaNeT .@TShoreMD @MyelomanMarkMD @RubenNiesvizky @kvbesien @CornellBMT @MyelomaCenter. https://t